Management of AFB‑Positive, GeneXpert‑Negative Sputum

Immediate Antituberculosis Therapy

• Initiate empiric four‑drug therapy (isoniazid, rifampin, pyrazinamide, ethambutol) as soon as an AFB‑positive smear is identified, even when GeneXpert is negative, because the smear indicates high transmission risk. 1
• Do not wait for mycobacterial culture results before starting treatment; delaying therapy increases the risk of transmission and disease progression. 1
• In settings where local isoniazid resistance exceeds 4 %, a four‑drug regimen is required; if resistance is < 4 % and the patient has documented contact with drug‑susceptible TB, a three‑drug regimen may be considered, but four drugs remain the safer default in most U.S. practice. 1

Respiratory Isolation

• Place the patient in airborne isolation immediately upon identification of AFB‑positive sputum. 1
• Maintain isolation until the patient shows clinical improvement and has three consecutive negative AFB smears obtained on separate days. 1
• A single negative GeneXpert result does not justify discontinuing isolation when the initial smear was positive. 1

Diagnostic Evaluation While on Therapy

• Send the same specimen (or collect new specimens) for mycobacterial culture on both liquid (MGIT) and solid media, as culture remains the gold‑standard test. 4
• Request rapid drug‑susceptibility testing (especially rifampin and isoniazid) as soon as the culture turns positive. 6
• Collect at least three sputum specimens for AFB smear and culture to maximize diagnostic yield. 2
• If a false‑negative GeneXpert is suspected (e.g., due to inhibitors), evaluate for assay inhibition and repeat the test on a fresh specimen. 4

Interpretation of GeneXpert Sensitivity

• GeneXpert detects ≈ 96 % of TB cases when the smear is positive, meaning it still misses about 4 % of true tuberculosis infections. 4
• A discordant result (AFB‑positive / GeneXpert‑negative) may reflect (1) a low bacterial load below the assay’s detection limit, (2) infection with nontuberculous mycobacteria (NTM), or (3) technical/inhibitor issues with the assay. 4

Treatment Regimens Based on Culture Results

Culture Grows Mycobacterium tuberculosis

• Continue the standard six‑month regimen: two months of intensive phase with four drugs (INH, RIF, PZA, EMB) followed by four months of continuation phase with INH + RIF. 2
• If susceptibility testing shows the isolate is sensitive to INH, RIF, and PZA, discontinue ethambutol after the intensive phase. 1
• Perform monthly sputum smear and culture monitoring; the majority of patients achieve conversion to negative by three months of effective therapy. 7

Culture Remains Negative at 8 Weeks

• Re‑evaluate clinical symptoms and repeat chest radiography at two months of therapy. 2
• When the patient demonstrates clinical and radiographic improvement and no alternative diagnosis is identified, continue treatment as culture‑negative tuberculosis. 2
• Shorten total therapy to four months of INH + RIF (provided the four‑drug intensive phase was completed while awaiting cultures). 2
• If there is no clinical or radiographic improvement at two months, reconsider the diagnosis and investigate other etiologies (e.g., fungal infection, malignancy, other bacteria). 2

Monitoring During Therapy

Clinical and Microbiological Follow‑up

• Assess medication adherence, symptom resolution (cough, fever, night sweats, weight gain), and adverse effects at every monthly visit. 8
• Perform chest radiography at the end of the intensive phase (≈ 2 months) to document radiographic response. 8

Laboratory Safety Monitoring

• Obtain baseline liver function tests, bilirubin, creatinine, complete blood count, and HIV status before initiating therapy. 10
• Monitor liver enzymes monthly in patients with baseline abnormalities, chronic liver disease, pregnancy, or new hepatotoxic symptoms. 10
• If ALT/AST rises to ≥ 5 × the upper limit of normal or bilirubin becomes elevated, immediately discontinue rifampin, isoniazid, and pyrazinamide. 10
• Conduct monthly visual acuity and color‑vision testing for all patients receiving ethambutol to detect early optic neuritis. 10

Management of Suspected Treatment Failure and Drug Resistance

• When treatment failure is suspected (persistent positive smears or cultures after three months), never add a single new drug; doing so creates functional monotherapy and promotes resistance. 7
• Add at least two (preferably three) new agents to which the organism is likely susceptible when resistance is suspected. 6

All statements are supported by the cited peer‑reviewed literature; the level of evidence is not explicitly graded in the source material.